S&P 500   5,069.53 (-0.38%)
DOW   39,069.23 (-0.16%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
S&P 500   5,069.53 (-0.38%)
DOW   39,069.23 (-0.16%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
S&P 500   5,069.53 (-0.38%)
DOW   39,069.23 (-0.16%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
S&P 500   5,069.53 (-0.38%)
DOW   39,069.23 (-0.16%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
NASDAQ:IRWD

Ironwood Pharmaceuticals (IRWD) Stock Price, News & Analysis

$15.03
-0.04 (-0.27%)
(As of 02/26/2024 ET)
Today's Range
$14.96
$15.24
50-Day Range
$11.00
$15.45
52-Week Range
$8.07
$15.70
Volume
1.89 million shs
Average Volume
3.45 million shs
Market Capitalization
$2.35 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00

Ironwood Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
39.7% Upside
$21.00 Price Target
Short Interest
Healthy
9.51% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.94
Upright™ Environmental Score
News Sentiment
0.36mentions of Ironwood Pharmaceuticals in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$4.16 M Sold Last Quarter
Proj. Earnings Growth
41.89%
From $0.74 to $1.05 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.35 out of 5 stars

Medical Sector

118th out of 942 stocks

Pharmaceutical Preparations Industry

42nd out of 425 stocks


IRWD stock logo

About Ironwood Pharmaceuticals Stock (NASDAQ:IRWD)

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

IRWD Stock Price History

IRWD Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Ironwood (IRWD) Q4 Earnings Miss, Revenues Beat Marginally
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
A Preview Of Ironwood Pharmaceuticals's Earnings
IRWD Apr 2024 15.000 call
Ironwood Pharmaceuticals Inc. Cl A
See More Headlines
Receive IRWD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ironwood Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
2/26/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:IRWD
CUSIP
46333X10
Employees
219
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.00
High Stock Price Target
$22.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+39.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-1,002,240,000.00
Net Margins
-226.37%
Pretax Margin
-214.14%

Debt

Sales & Book Value

Annual Sales
$442.74 million
Book Value
($2.21) per share

Miscellaneous

Free Float
136,024,000
Market Cap
$2.35 billion
Optionable
Optionable
Beta
0.65
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives















IRWD Stock Analysis - Frequently Asked Questions

Should I buy or sell Ironwood Pharmaceuticals stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IRWD shares.
View IRWD analyst ratings
or view top-rated stocks.

What is Ironwood Pharmaceuticals' stock price target for 2024?

5 analysts have issued 12 month price objectives for Ironwood Pharmaceuticals' shares. Their IRWD share price targets range from $20.00 to $22.00. On average, they expect the company's share price to reach $21.00 in the next year. This suggests a possible upside of 39.7% from the stock's current price.
View analysts price targets for IRWD
or view top-rated stocks among Wall Street analysts.

How have IRWD shares performed in 2024?

Ironwood Pharmaceuticals' stock was trading at $11.44 at the beginning of 2024. Since then, IRWD stock has increased by 31.4% and is now trading at $15.03.
View the best growth stocks for 2024 here
.

Are investors shorting Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals saw a drop in short interest in January. As of January 31st, there was short interest totaling 14,460,000 shares, a drop of 10.1% from the January 15th total of 16,080,000 shares. Based on an average daily volume of 2,660,000 shares, the short-interest ratio is presently 5.4 days. Currently, 9.5% of the company's stock are short sold.
View Ironwood Pharmaceuticals' Short Interest
.

When is Ironwood Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our IRWD earnings forecast
.

How were Ironwood Pharmaceuticals' earnings last quarter?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced its quarterly earnings data on Thursday, November, 9th. The biotechnology company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.17 by $0.05. The biotechnology company had revenue of $113.74 million for the quarter, compared to analysts' expectations of $112.90 million. Ironwood Pharmaceuticals had a negative net margin of 226.37% and a negative trailing twelve-month return on equity of 185.45%. Ironwood Pharmaceuticals's quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.28 earnings per share.

What guidance has Ironwood Pharmaceuticals issued on next quarter's earnings?

Ironwood Pharmaceuticals updated its FY 2023 earnings guidance on Monday, January, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $435.0 million-$450.0 million, compared to the consensus revenue estimate of $444.0 million.

What is Mark Mallon's approval rating as Ironwood Pharmaceuticals' CEO?

7 employees have rated Ironwood Pharmaceuticals Chief Executive Officer Mark Mallon on Glassdoor.com. Mark Mallon has an approval rating of 93% among the company's employees. This puts Mark Mallon in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Ironwood Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), NIC (EGOV), Athabasca Oil (ATH), Allergan (AGN), Aegean Marine Petroleum Network (ANW), Micron Technology (MU) and Starbucks (SBUX).

Who are Ironwood Pharmaceuticals' major shareholders?

Ironwood Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.27%), LSV Asset Management (4.34%), Armistice Capital LLC (3.65%), Victory Capital Management Inc. (2.71%), Brown Capital Management LLC (2.38%) and Dimensional Fund Advisors LP (1.97%). Insiders that own company stock include Alexander J Denner, Andrew Davis, Jason Rickard, Julie Mchugh, Mark G Currie, Marla L Kessler, Michael Shetzline, Minardo John, Ronald Silver, Sravan Kumar Emany, Thomas A Mccourt and Timothy M O'reilly.
View institutional ownership trends
.

How do I buy shares of Ironwood Pharmaceuticals?

Shares of IRWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IRWD) was last updated on 2/26/2024 by MarketBeat.com Staff